Methods Pts with stage IIIB or IV disease who had not progressed on four to six cycles of
platinum-based chemotherapy, with at least one measurable lesion, and an Eastern …

Methods This study reviewed the medical history of 6020 lung cancer patients who
underwent PD-1/PD-L1 inhibitors and 1563 who received anlotinib at Shanghai Chest …

Background Anlotinib (AL3818) is a novel multi-target angioenesis TKI targeting the VEGFR,
FGFR, PDGFR and c-Kit. In the ALTER0303 trial, Anlotinib as third-line treatment …

Background Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR,
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …

Purpose Anlotinib is widely used in the clinical treatment of non-small cell lung cancer
(NSCLC), alone or in combination with other anticancer drugs. The aim of this study was to …

Anlotinib is a novel multitarget tyrosine kinase inhibitor, which has been indicated to inhibit
both tumor angiogenesis and signal transduction pathways associated with proliferation …

e21073 Background: Anlotinib, a multi-target tyrosine kinase inhibitor antiangiogenic drug,
had been recommended by guideline for the 3 lines or more treatment of non-small cell lung …

Background Chemotherapy or Immunotherapy alone as 2 nd-line treatment in driver-
negative advanced NSCLC has unsatisfactory efficacy. We previously reported some results …

Background The advent of immunotherapy has revolutionized non-small cell lung cancer
(NSCLC) treatment. Anlotinib (AN), a multitargeted tyrosine kinase inhibitor, holds promise …

Background Pre-clinical and clinical evidences support that simultaneous blockade of
programmed death-1 (PD-1) and vascular endothelial growth factor receptor (VEGFR) can …